Objective
Peripheral Arterial Disease (PAD) is caused by the deposition of fatty material on the inner walls of peripheral arteries causing reducing perfusion and local nutrition to the muscles and skin. The condition affect 202 million people globally and is increasing at a rate of 20% per annum due to an aging population and epidemic growth of diabetes. The social costs amounts to $210 - 380 billion per annum.
Behavioural changes such as smoking cessation, healthy nutrition and exercise is recommended to reduce impact and risk. When the condition worsens, patients ability to walk and exercise is reduced. When disease progress to critical limb ischemia (unbearable pain and chronic wounds), the patients follow a trajectory towards costly vascular surgery or amputation.
FlowOx targets the gap in care with a patented, cost effective and clinically promising home treatment solution. In order to secure the successful introduction of FlowOx into the market by 2020, resources are required to fill the following gaps in innovation:1) strong clinical evidence of efficacy 2) health economic assessment 3) design for large scale manufacturing and 4) a validated commercial model Germany, UK and Scandinavia. These 4 challenges will be addressed in the FlowOx project over a 30-month period.
The Fast Track to Innovation Pilot program was selected to support a resource demanding and technically challenging stage of the product roadmap. The support enables Otivio to join forces with a medical device manufacturer, Innokas Medical, Finland, and UK based Univ. of Salford and Univ. of Bangor with extensive experience in clinical and health economic studies. The FlowOx project enables Otivio and Innokas to enter the world-wide PAD market, gaining a strong market positon with a home care device for PAD treatment and expected sales of over €220 million within 5 years of launch.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine surgery
- medical and health sciences clinical medicine endocrinology diabetes
- medical and health sciences health sciences nutrition
- medical and health sciences clinical medicine peripheral vascular disease
- social sciences economics and business business and management commerce
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EC - Horizon 2020 Framework Programme
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2. - PRIORITY 'Industrial leadership'
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
IA - Innovation action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-FTIPilot-2016
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
0349 OSLO
Norway
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.